Vaxart, Inc share price logo

Vaxart, Inc

NASDAQ: VXRT

Small Cap

$0.51

(+0.57%)

as on

Vaxart, Inc Stock Performance

as on June 27, 2026 at 6:53 am IST

  • Day's Low

    Day's High

    $0.50
    $0.54
    downward going graph

    1.96%

    Downside

    5.88%

    Upside

    downward going graph

  • 52 Week's Low

    52 Week's High

    $0.30
    $0.84
    downward going graph

    41.18%

    Downside

    65.67%

    Upside

    downward going graph

Vaxart, Inc share price movements today

Previous Close
$0.51
Open
$0.51
Volume
1.3M
Day's Low - High
$0.50 - $0.54
52 Week Low - High
$0.30 - $0.84

Vaxart, Inc Historical Returns

1 Month Return
-19.84 %
3 Month Return
-25.27 %
1 Year Return
-4.78 %
3 Year Return
-31.88 %
5 Year Return
-94.06 %

Vaxart, Inc Stock Fundamentals & Key Indicators

Check Vaxart, Inc market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$125.9M

EPS (TTM)

0.06

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

3.25

Industry PE ratio

-3.9121076233183856

PEG Ratio

0

EBITDA

45.6M

Revenue (TTM)

255.6M

Profit Margin

14.51%

Return On Equity TTM

53.10%

Vaxart, Inc Stock Valuation

Track how Vaxart, Inc P/E has moved over time to understand its valuation trends.

Vaxart, Inc in the last 5 years

  • Overview

  • Trends

Lowest (-15.24x)

September 30, 2021

Industry (-3.91x)

June 26, 2026

Today (3.25x)

June 26, 2026

Highest (5.92x)

December 31, 2025

LowHigh

Today’s Price to Earnings Ratio: 3.25x

Vaxart, Inc vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Vaxart, Inc with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %Dividend Yield %
Vaxart, Inc image
Vaxart, Inc
BUY$125.9M-94.06%3.2514.51%NA
Alnylam Pharmaceuticals Inc. image
Alnylam Pharmaceuticals Inc.
BUY$39.3B67.15%74.0712.55%NA
Vertex Pharmaceuticals Inc. image
Vertex Pharmaceuticals Inc.
BUY$120.6B147.08%28.1735.51%NA
Regeneron Pharmaceuticals Inc. image
Regeneron Pharmaceuticals Inc.
BUY$65.4B12.64%15.2229.65%0.58%

Stock Returns calculator for Vaxart, Inc Stock including INR - Dollar returns

The Vaxart, Inc stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Vaxart, Inc investment value today

Current value as on today

₹1,05,957

Returns

₹5,957

(+5.96%)

Returns from Vaxart, Inc Stock

-₹3,774 (-3.77%)

Dollar Impact

₹9,731 (+9.73%)

Analyst Recommendation on Vaxart, Inc Stock

Based on 9 analysts

BUY

88.89%

Buy

11.11%

Hold

0.00%

Sell

Based on 9 analysts, 88.89% of analysts recommend a 'BUY' rating for Vaxart, Inc. Average target price of $3

Vaxart, Inc Share Price Target

Get share price movements and forecasts by analysts on Vaxart, Inc.

What analysts predicted

83%UPSIDE

Target Price

$3

Current Price

$0.51

Analyzed by

9 Analysts

Target

$3.00

Vaxart, Inc target price $3, a slight upside of 83% compared to current price of $0.51. According to 9 analysts rating.

Indian Investors' Interest in Vaxart, Inc Stock

Search interest for Vaxart, Inc Stock has decreased by -30% in the last 30 days, reflecting a downward trend in search activity.

Time period: to

Change:-30% versus previous 30 day period

Vaxart, Inc Quarterly Profit & Loss

All numbers in Millions USD

Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Total Revenue
3
2
6
4
15
20
39
72
104
39
Gross Profit
2
2
6
4
15
20
39
72
104
39
Operating Income
-16
-24
-16
-14
-11
-14
-14
-7
55
5
EBITDA
-15
-21
-13
-11
-8
-12
-12
-5
57
6
Interest Expense
0
0
0
0
0
0
0
0
0
0
Depreciation
2
2
2
2
2
2
2
2
2
1
Income Before Tax
-17
-24
-16
-14
-11
-15
-14
-8
55
5
Income Tax Expense
0
0
0
0
0
0
0
0
0
0
Net Income
-17
-24
-16
-14
-11
-15
-14
-8
55
5
Net Profit Margin
-535.44%
-1119.53%
-257.24%
-285.42%
-78.93%
-74.68%
-37.72%
-11.24%
52.81%
13.20%

Vaxart, Inc Annual Profit & Loss

All numbers in Millions USD

Dec 2016
Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
9
5
4
9
4
0
0
7
28
237
Gross Profit
9
-6
-13
9
-15
-47
0
2
28
237
Operating Income
-25
-9
-21
-15
-30
-72
-114
-83
-66
18
EBITDA
-25
-8
-12
-12
-28
-66
-100
-72
-54
28
Interest Expense
0
1
2
2
1
1
1
1
2
2
Depreciation
0
-
3
3
2
4
5
8
8
8
Income Before Tax
-25
-9
-17
-18
-31
-70
-107
-82
-66
16
Income Tax Expense
0
0
0
0
0
0
0
0
0
0
Net Income
-25
-12
-18
-18
-32
-70
-107
-82
-66
16
Net Profit Margin
-273.12%
-213.39%
-432.96%
-189.06%
-796.34%
-7900.22%
-100708.41%
-1117.56%
-233.27%
6.88%

Vaxart, Inc Quarterly Cash Flow

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Net Income
-24
-16
-14
-11
-15
-14
-8
55
5
Operating Cash Flow
-21
-12
-4
-7
-9
-15
2
30
-2
Investing Cash Flow
-5
-9
-17
10
13
7
-5
1
0
Financing Cash Flow
18
38
0
0
0
0
0
4
0
Change in Cash
-8
16
-21
3
3
-8
-3
36
-3

Vaxart, Inc Annual Cash Flow

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
-9
-18
-18
-32
-70
-107
-82
-66
16
Operating Cash Flow
-10
-14
-13
-23
-59
-94
-70
-44
7
Investing Cash Flow
3
26
0
-1
-49
-20
43
-21
16
Financing Cash Flow
0
-1
15
138
125
17
15
56
4
Change in Cash
-6
9
2
113
16
-97
-11
-9
28

Global Institutional Holdings in Vaxart, Inc

Funds
Holdings
Creative Planning Inc
0%
LVM Capital Management Ltd.
0.01%
Vanguard Group Inc
4.54%
BlackRock Inc
0%
Sio Capital Management, LLC
2.45%
See all

Insights on Vaxart, Inc

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 6 months, VXRT stock has moved up by 55.9%

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Regeneron Pharmaceuticals, Inc. Common Stock has given 21.5% return, outperforming this stock by 12.4%

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, Vaxart, Inc Common Stock has experienced a drawdown of -26.1%, however Alnylam Pharmaceuticals, Inc. Common Stock resisted the overall trend and outperformed by 14.5%

About Vaxart, Inc

Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its vector-adjuvant-antigen standardized technology proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII; COVID-19 Vaccine, which is in Phase 2b clinical trial for the treatment of SARS-CoV-1, SARS-CoV-2, and Middle East respiratory syndrome coronavirus; Seasonal Influenza vaccine, which is in Phase 2 clinical trial, to treat H1N1 Influenza; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions. The company also provides VAAST (Vector-Adjuvant-Antigen Standardized Technology) Platform, a unique modular vaccine platform. It has a license agreement with Altesa Biosciences, Inc. to develop and commercialize Vapendavir, a capsid-binding broad-spectrum antiviral. Vaxart, Inc. is headquartered in South San Francisco, California.
OrganisationVaxart, Inc
Headquarters310 Utah Avenue, South San Francisco, CA, United States, 94080
IndustryBiotechnology
CEOMr. Steven Lo
E-voting on sharesClick here to vote

Key Management of Vaxart, Inc

Name

Title

Dr. Rajesh Kapoor Ph.D.

Senior Vice President of Quality

Mr. Steven Lo

President, CEO & Director

Dr. Sean N. Tucker Ph.D.

Senior VP & Chief Scientific Officer

Dr. James F. Cummings M.D.

Chief Medical Officer

Mr. Jeroen Grasman M.B.A.

CFO, Principal Accounting Officer & Principal Financial Officer

Mr. Edward B. Berg

Senior VP & General Counsel

Ms. Laurie Hastings

Senior Vice President of Human Resources

FAQs

What is Vaxart, Inc share price today?

Vaxart, Inc share price today is $0.51 as on at the close of the market. Vaxart, Inc share today touched a day high of $0.54 and a low of $0.5.

What is the 52 week high and 52 week low for Vaxart, Inc share?

Vaxart, Inc share touched a 52 week high of $0.84 on and a 52 week low of $0.3 on . Vaxart, Inc stock price today i.e. is closed at $0.51,which is 39.64% down from its 52 week high and 70.00% up from its 52 week low.

What is Vaxart, Inc's market capitalisation today?

Vaxart, Inc market capitalisation is $0.00T as on .

How to invest in Vaxart, Inc Stock (VXRT) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Vaxart, Inc on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Vaxart, Inc Shares that will get you 2.9412 shares as per Vaxart, Inc share price of $0.51 per share as on June 27, 2026 at 1:23 am IST.

What is the minimum amount required to buy Vaxart, Inc Stock (VXRT) from India?

Indian investors can start investing in Vaxart, Inc (VXRT) shares with as little as ₹94.3 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹943.00 in Vaxart, Inc stock (as per the Rupee-Dollar exchange rate as on ). Based on Vaxart, Inc share’s latest price of $0.51 as on June 27, 2026 at 1:23 am IST, you will get 19.6078 shares of Vaxart, Inc. Learn more about fractional shares .

What are the returns that Vaxart, Inc has given to Indian investors in the last 5 years?

Vaxart, Inc stock has given -94.06% share price returns and 27.55% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?